Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment

AIDS

Volumn 27, Issue 17, 2013, Pages 2725-2734

  Hua, Lei ^a   Andersen, Janet W ^a   Daar, Eric S ^b   Glesby, Marshall J ^c   Hollabaugh, Kimberly ^a   Tierney, Camlin ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antiretroviral treatment; CD4+ cell responses; Early virologic failure; Hepatitis C virus HIV coinfection; Treatment naive

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; CD4 ANTIGEN; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DEATH; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICATION COMPLIANCE; MIXED INFECTION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RACE DIFFERENCE; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS AS TOPIC; COINFECTION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84888295569     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/01.aids.0000432470.46379.dd     Document Type: Article

References (43)

1. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-837.
2. Potter M, Odueyungbo A, Yang H, Saeed S, Klein MB. Impact of hepatitis C viral replication on CD4R T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. AIDS 2010; 24:1857-1865.
3. Agbaji O, Thio CL, Meloni S, Graham C, Muazu M, Nimzing L, et al. Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria. J Acquir Immune Defic Syndr 2013; 62:204-207.
4. Motta D, Brianese N, Foca E, Nasta P, Maggiolo F, Fabbiani M, et al. Virological effectiveness and CD4R T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received. AIDS Res Ther 2012; 9:18.
5. Pineda J, Romero-Gómez M, D́az-Garća F, Girón-González J, Montero J, Torre-Cisneros J, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005; 41:779-789.
6. Thein H, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: A metaanalysis. AIDS 2008; 22:1979-1991.
7. Thein H, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression. Hepatology 2008; 48:418-431.
8. Sulkowski MS, Mehta SH, Torbenson MS, Higgins Y, Brinkley SC, deOcaRM, et al. Rapidfibrosis progressionamong HIV/hepatitis C virus-co-infected adults. AIDS 2007; 21:2209-2216.
9. Rossi SJ, Volberding PA, Wright TL. Does hepatitis C virus infection increase the risk of HIV disease progression JAMA 2002; 288:241-243.
10. Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 2011; 8:12-22.
11. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-1805.
12. Luca AD, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002; 162:2125-2132.
13. Lincoln D, Petoumenos K, Dore G. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 2003; 4:241-249.
14. Seminari E, Tinelli C, Ravasi G, Ripamonti D, Ladisa N, Mario N, et al. Hepatitis C infection on immune recovery in HIVpositive patients on successful HAART: the role of genotype. Curr HIV Res 2010; 8:186-193.
15. Chen T, Ding EL, Seage GR III, Kim AY. Meta-analysis: Increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009; 49:1605-1615.
16. Miller MF, Haley C, Koziel MJ, Rowley CF. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: A meta-analysis. Clin Infect Dis 2005; 41:713-720.
17. Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004; 18:1169-1177.
18. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. CD4R T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003; 163:2187-2195.
19. Matthews GV, Dore GJ. HIV and hepatitis C coinfection. J Gastroenterol Hepatol 2008; 23:1000-1008.
20. Sulkowski MS, Moore rD, Meehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288:199-206.
21. Stebbing J, Waters L, Mandalia S, Bower M, Nelson M, Gazzard B. Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4R cell count but does increase the likelihood of AIDS-defining events. Clin Infect Dis 2005; 41:906-911.
22. Weimer LE, Fragola V, Floridia M, Guaraldi G, Ladisa N, Francisci D, et al. Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. J Antimicrob Chemother 2013; 68:193-199.
23. Rockstroh J, Teppler H, Zhao J, Sklar P, Harvey C, Strohmaier K, et al. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus co-infection. HIV Med 2012; 13:127-131.
24. Than N, Sungkanuparph S, Maek-A-Nantawat W, Kaewkungwal J, Pitisuttithum P. Comparison of clinical outcomes between HIV-infected patients with and without HCV coinfection in a resource-limited setting. Southeast Asian J Trop Med Public Health 2011; 43:646-651.
25. Collazos J, Carton JA, Asensi V. Evaluation of the possible influence of hepatitis C virus and liver fibrosis on HIV type 1 immunological and virological outcomes. HIV Med 2011; 12:308-315.
26. Rockstroh J, Mocroft A, Soriano V, Tural C, Losso M, Horban A, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992-1002.
27. Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore GJ. HIV and hepatitis C co-infection within the CAESAR study. HIV Med 2004; 5:174-179.
28. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: A cohort study. AIDS 2004; 18:2039-2045.
29. Monforte AD, Cozzi-Lepri A, Castagna A, Antinori A, Lua AD, Mussini C, et al. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. Clin Infect Dis 2009; 49:612-622.
30. Gross R, Tierney C, Andrade A, Lalama C, Rosenkranz S, Eshleman SH, et al. Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: A randomized trial. Arch Intern Med 2010; 169:1224-1232.
31. Flexner CW, Tierney C, Gross R, Andrade A, Lalama C, Eshleman SH, et al. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis 2010; 50:1041-1052.
32. Gulick R, Ribaudo H, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, et al. Triple-nucleoside regimens versus efavirenzcontaining regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861.
33. Riddler SA, Haubrich RH, DiRienzo G, Peeples L, PowderlyWG, Klingman KL, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106.
34. Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230-2240.
35. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154:445-456.
36. Sax P, Tierney C, Collier A, Daar E, Mollan K, Budhathoki C, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011; 204:1191-1201.
37. Snyder N, Gajula L, Xiao S, Grady J, Luxon B, Lau D, et al. APRI: An easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Gastroenterol Hepatol 2006; 40:535-542.
38. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with Liver Biopsy and FibroTest. Hepatology 2007; 46:32-36.
39. Kovacs A, Karim R, Mack WJ, Xu J, Chen Z, Operskalski E, et al. Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis 2010; 201:823-834.
40. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Shafer KP, et al. Relationship between T cell activation and CD4R T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 97:126-133.
41. Gonzalez VD, Falconer C, Blom KG, Reichard O, Morn B, Laursen AL, et al. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol 2009; 8311407-11411.
42. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 Recommendations of the International Antiviral Society-USA Panel. JAMA 2012; 308:387-402.
43. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/ contentfiles/lvguidelines/AdultandAdolescentGL.pdf [Accessed 09 June 2012].